Travere Therapeutics Inc [TVTX] stock is trading at $40.28, up 13.91%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The TVTX shares have gain 18.86% over the last week, with a monthly amount glided 12.55%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Travere Therapeutics Inc [NASDAQ: TVTX] stock has seen the most recent analyst activity on October 31, 2025, when Citigroup reiterated its Buy rating and also boosted its price target to $48 from $34. On June 11, 2025, Citigroup reiterated its Buy rating and revised its price target to $32 on the stock. Cantor Fitzgerald started tracking the stock assigning an Overweight rating. Wells Fargo upgraded its rating to an Overweight and raised its price target to $27 on October 21, 2024. In a note dated September 09, 2024, Guggenheim upgraded a Buy rating on this stock but restated the target price of $25.
Travere Therapeutics Inc [TVTX] stock has fluctuated between $12.91 and $37.50 over the past year. Currently, Wall Street analysts expect the stock to reach $35 within the next 12 months. Travere Therapeutics Inc [NASDAQ: TVTX] shares were valued at $40.28 at the most recent close of the market. An investor can expect a potential drop of -13.11% based on the average TVTX price forecast.
Analyzing the TVTX fundamentals
Travere Therapeutics Inc [NASDAQ:TVTX] reported sales of 435.83M for the trailing twelve months, which represents a growth of 162.11%. Gross Profit Margin for this corporation currently stands at 0.54% with Operating Profit Margin at -0.21%, Pretax Profit Margin comes in at -0.2%, and Net Profit Margin reading is -0.2%. To continue investigating profitability, this company’s Return on Assets is posted at -0.16, Equity is -1.79 and Total Capital is -0.22. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 4.48.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 36.82 points at the first support level, and at 33.35 for the second support level. However, for the 1st resistance point, the stock is sitting at 42.94, and for the 2nd resistance point, it is at 45.59.
Ratios To Look Out For
For context, Travere Therapeutics Inc’s Current Ratio is 2.75. Also, the Quick Ratio is 2.71, while the Cash Ratio stands at 0.82. Considering the valuation of this stock, the price to sales ratio is 8.27, the price to book ratio is 48.98.
Transactions by insiders
Recent insider trading involved Calvin Sandra, SVP, CHIEF ACCOUNTING OFFICER, that happened on Dec 15 ’25 when 2910.0 shares were sold. Officer, SANDRA CALVIN completed a deal on Dec 15 ’25 to buy 2910.0 shares. Meanwhile, CHIEF FINANCIAL OFFICER Cline Christopher R. sold 20000.0 shares on Dec 01 ’25.
